Brainsway Ltd. American Depositary Shares

BrainsWay received FDA clearance to use Deep TMS™ as an adjunct therapy for major depressive disorder in adolescents aged 15-21, based on a comprehensive dataset of 1,120 patients showing significant symptom improvement and safety.

Brainsway Ltd. Sponsored ADR (BWAY) has outperformed the broader Medical sector and its own industry group so far this year, with a year-to-date return of around 45% compared to the sector's average of 8.6%. Another stock, Intuitive Surgical, Inc. (ISRG), has also outperformed the sector.

BrainsWay's (BWAY) latest exclusive multi-year distribution agreement is likely to provide improved patient care in Canada.